Literature DB >> 2691161

Autoantibodies in scleroderma.

K M Pollard1, G Reimer, E M Tan.   

Abstract

In scleroderma a profusion of circulating autoantibodies have now been defined. They include autoantibodies to Scl-70 or DNA topoisomerase 1, and to centromere/kinetochore proteins of 17.80 and 140 kilodaltons. In addition, there are several antigens which are resident primarily in the nucleolus and they are RNA polymerase 1, PM-Scl, fibrillarin and 7-2 ribonucleoprotein. Antibody to Scl-70 has been found primarily in the diffuse form of scleroderma and antibody to the centromere/kinetochore proteins in the CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia) subset of scleroderma. Autoantibodies to the nucleolar antigens RNA polymerase 1, PM-Scl, fibrillarin and 7-2 RNP have been detected in at least 10% of all patients with scleroderma. For several reasons which are discussed, it appears that the autoantibody response in scleroderma is antigen-driven and further that the autoantigens involved in this disease are present at some time in the nucleolus. These observations may be providing clues to some of the basic mechanisms initiating autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2691161

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Methods to detect antifibrillarin antibodies in patients with systemic sclerosis (SSc): a comparison.

Authors:  Josefina Huerta García; Monica Delgado Osuna; Filiberto Martinez Castrejon; Laura Guzman Enriquez; Pedro A Reyes; J Jesus Cortes Hermosillo
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

3.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

Review 4.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations.

Authors:  H Van Eenennaam; J H P Vogelzangs; L Bisschops; L C J Te Boome; H P Seelig; M Renz; D-J De Rooij; R Brouwer; H Pluk; G J M Pruijn; W J Van Venrooij; F H J Van Den Hoogen
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

6.  A role for SUMOylation in snoRNP biogenesis revealed by quantitative proteomics.

Authors:  Belinda J Westman; Angus I Lamond
Journal:  Nucleus       Date:  2011 Jan-Feb       Impact factor: 4.197

7.  Anticentromere antibody induced by immunization with centromere protein a and Freund's complete adjuvant may interfere with mouse oocyte meiosis.

Authors:  Ying Ying; Shuang Liu; Yixuan Wu; Sichen Li; Qing Huang
Journal:  Reprod Biol Endocrinol       Date:  2021-04-01       Impact factor: 5.211

Review 8.  RNA 2'-O-Methylation (Nm) Modification in Human Diseases.

Authors:  Dilyana G Dimitrova; Laure Teysset; Clément Carré
Journal:  Genes (Basel)       Date:  2019-02-05       Impact factor: 4.096

9.  Fibrillarin is essential for early development and required for accumulation of an intron-encoded small nucleolar RNA in the mouse.

Authors:  Kathryn Newton; Elisabeth Petfalski; David Tollervey; Javier F Cáceres
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.